Stage IV rectal cancer treatment complicated by repeated heart-related side effects

Patient Info: Anonymized, Female | Stage IV

Biomarkers: p53 mutation

Metastatic Site: liver

After responding again to adapted chemotherapy and NanoKnife ablation, she had no evidence of active disease and had not restarted chemotherapy; ileostomy reversal was planned.

PubMed CentralRead more →

Severe but reversible neurologic side effects during 5-fluorouracil treatment for Stage IV colorectal cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: liver

His confusion, dysarthria and ataxia resolved within 24 hours with intravenous hydration, and the MRI lesion resolved within 1 month. The cancer later progressed on restaging, prompting another treatment change.

PubMed CentralRead more →

Metastatic Colorectal Cancer Treated With S-1 After 5-FU Cardiotoxicity

Patient Info: Anonymized, male, 60s

Biomarkers: RAS-mutant

After progression in the liver despite prior systemic and liver-directed treatment, he started S-1, oxaliplatin and bevacizumab; the first cycle caused no cardiac complication and treatment continued as an outpatient.

PubMed CentralRead more →

ERBB2-Mutated Stage III Lung Cancer With Liver Recurrence and Multiple Lines of Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: liver

After 6 months of disease control on vinorelbine plus trastuzumab, the cancer progressed in all sites and she chose hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Cancer With Extensive Bone Metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion. A PIK3CA mutation was later detected at progression and considered a possible resistance mechanism.

Metastatic Site: bone

After progression on pemetrexed following several earlier treatment lines, she transitioned to hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Limited Disease Control Across Multiple Therapies

Patient Info: Anonymized, female

Biomarkers: ERBB2 V776delinsVC mutation

After temporary stable disease when bevacizumab was added to chemotherapy, the cancer progressed on trastuzumab plus paclitaxel and then erlotinib.

PubMed CentralRead more →

Metastatic Low-Grade Serous Ovarian Cancer Causing Severe Pulmonary Hypertension

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: pleura, pulmonary arteries

She died on hospital day 29 after rapidly progressive pulmonary hypertension. Autopsy attributed the pulmonary hypertension to metastatic ovarian serous carcinoma with pulmonary arterial tumor emboli.

PubMed CentralRead more →

Stage III BRCA1 Ovarian Cancer: Meredith's Survivor Story

Patient Info: Meredith Ippolito, female | Stage III

Biomarkers: BRCA1 mutation

Meredith was told she was cancer-free in April 2009 and continued follow-up visits every 6 months.

MD AndersonRead more →

Stage IV Ovarian Cancer: Bre's Patient Story

Patient Info: Bre Tipps, female, Under 40 | Stage IV

A recent CT scan showed the remaining tumors calcifying and dying during hormonal therapy, although the patient expected to need ongoing ovarian cancer treatment.

MD AndersonRead more →

Sigmoid colon cancer: complete response after repeated metastatic recurrences and multimodal therapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS/NRAS/BRAF status not reported; CEA elevation used for recurrence monitoring

Metastatic Site: left lung, mediastinal lymph nodes, left adrenal…

By 2011, all metastatic lesions had achieved complete response; nearly 1 year after the last adrenal irradiation, no recurrence had been detected.

PubMed CentralRead more →

EGFR L858R-mutant Stage IV lung adenocarcinoma managed after gefitinib-induced lung injury

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver, bone, hilar lymph nodes, mediastinal lymph…

Gefitinib produced early tumor shrinkage but was stopped for interstitial lung disease; subsequent carboplatin, pemetrexed, and bevacizumab produced a good response, while variceal bleeding was controlled with endoscopic treatment.

PubMed CentralRead more →

Recurrent Stage III Ovarian Cancer in a BRCA1 Carrier Treated With Multiple Therapies

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: BRCA1 mutation

By late 2011, hilar nodal disease was slowly progressing and bevacizumab was started for the recurrent ovarian cancer.

PubMed CentralRead more →

Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury

Patient Info: Anonymized, female, 70+ | Stage III

After further intra-abdominal cancer progression and severe kidney injury, she developed seizures, encephalopathy, and limb ischemia and died 1 week after hospitalization in May 2011.

PubMed CentralRead more →

Stage IV NSCLC with choroidal metastasis responding to intravitreal bevacizumab

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: choroid of right eye

The right-eye choroidal metastasis showed complete local response after intravitreal bevacizumab, with pain resolution, vision improvement to 20/20, and no residual ocular tumor detected 10 months after treatment began.

PubMed CentralRead more →